[PRNewswire] ICP DAS - BMP to partake in the COMPAMED 2022, Germany for the
first time
(HSINCHU, Nov. 1, 2022 PRNewswire=연합뉴스) ICP DAS - BMP (Biomedical Polymers), a Taiwan medical TPU (thermoplastic polyurethane) supplier, will exhibit TPU pellets with 50% tungsten content (W50) for the first time in the COMPAMED 2022, Germany. The exhibition - a melting pot for high-tech solutions in the medical technology sector - takes place in DUSSELDORF from 14 to 17 November.
ICP DAS - BMP will showcase three series of highly stable medical-grade TPU pellets, namely, Alithane™ (ALP series), Durathane™ (ALC series), and Arothane™ (ARP series). This year, ICP DAS - BMP unveils a new range of pellets with a tungsten content of 30% (W30) and 50% (W50), respectively. As we advance, ICP DAS - BMP plans to develop pellets with 70% tungsten content (W70) and a new ARP-CHDM series in 2023.
All medical-grade TPU pellets by ICP DAS - BMP are 100% made in Taiwan and have superb biocompatibility, hydrolytic & chemical resistance, mechanical properties, and radiodensity; they can be customized and color-matched. To provide customers with the best service, ICP DAS - BMP offers shorter lead times and accepts smaller quantity orders.
Applications of medical-grade TPU pellets range from cancer treatment and urology devices to retainers, etc. Shortly after being established, ICP DAS - BMP achieves outstanding results domestically and internationally. Medical device manufacturers from South Korea, Israel, and France have chosen ICP DAS - BMP's trustworthy and high-quality TPUs.
Visit ICP DAS - BMP's booth at Hall 08B, Booth 8BC17-2, from 14 to 17 November 2022, and learn more about the upcoming ARP-CHDM series.
About ICP DAS - BMP
In response to the growing demand for TPUs in medical applications, in 2018, ICP DAS established a new business unit to develop and produce medical-grade TPUs, ICP DAS - BMP. The company has obtained ISO 13485 certification for its raw material warehouses and production lines.
ICP DAS - BMP has its own laboratories for polymerization, physical properties analysis, and cytotoxicity testing. All the TPUs supplied by ICP DAS - BMP are USP Class VI certified and compliant with the ISO 10993 international standard. Materials have passed skin sensitization and cytotoxicity tests according to ISO 10993-5 and ISO 10993-10. These enable ICP DAS - BMP to guarantee biocompatibility for medical device manufacturers.
For more details, please visit our website: https://bmp.icpdas.com/
For TPU products, solutions, and inquiries, contact us directly: sales_bmp@icpdas.com
Logo - https://mma.prnewswire.com/media/1934616/icpdas_bmp_Logo_Logo.jpg
(PRNewsfoto/ICP DAS Co., Ltd.)
Source: ICP DAS Co., Ltd.
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
first time
(HSINCHU, Nov. 1, 2022 PRNewswire=연합뉴스) ICP DAS - BMP (Biomedical Polymers), a Taiwan medical TPU (thermoplastic polyurethane) supplier, will exhibit TPU pellets with 50% tungsten content (W50) for the first time in the COMPAMED 2022, Germany. The exhibition - a melting pot for high-tech solutions in the medical technology sector - takes place in DUSSELDORF from 14 to 17 November.
ICP DAS - BMP will showcase three series of highly stable medical-grade TPU pellets, namely, Alithane™ (ALP series), Durathane™ (ALC series), and Arothane™ (ARP series). This year, ICP DAS - BMP unveils a new range of pellets with a tungsten content of 30% (W30) and 50% (W50), respectively. As we advance, ICP DAS - BMP plans to develop pellets with 70% tungsten content (W70) and a new ARP-CHDM series in 2023.
All medical-grade TPU pellets by ICP DAS - BMP are 100% made in Taiwan and have superb biocompatibility, hydrolytic & chemical resistance, mechanical properties, and radiodensity; they can be customized and color-matched. To provide customers with the best service, ICP DAS - BMP offers shorter lead times and accepts smaller quantity orders.
Applications of medical-grade TPU pellets range from cancer treatment and urology devices to retainers, etc. Shortly after being established, ICP DAS - BMP achieves outstanding results domestically and internationally. Medical device manufacturers from South Korea, Israel, and France have chosen ICP DAS - BMP's trustworthy and high-quality TPUs.
Visit ICP DAS - BMP's booth at Hall 08B, Booth 8BC17-2, from 14 to 17 November 2022, and learn more about the upcoming ARP-CHDM series.
About ICP DAS - BMP
In response to the growing demand for TPUs in medical applications, in 2018, ICP DAS established a new business unit to develop and produce medical-grade TPUs, ICP DAS - BMP. The company has obtained ISO 13485 certification for its raw material warehouses and production lines.
ICP DAS - BMP has its own laboratories for polymerization, physical properties analysis, and cytotoxicity testing. All the TPUs supplied by ICP DAS - BMP are USP Class VI certified and compliant with the ISO 10993 international standard. Materials have passed skin sensitization and cytotoxicity tests according to ISO 10993-5 and ISO 10993-10. These enable ICP DAS - BMP to guarantee biocompatibility for medical device manufacturers.
For more details, please visit our website: https://bmp.icpdas.com/
For TPU products, solutions, and inquiries, contact us directly: sales_bmp@icpdas.com
Logo - https://mma.prnewswire.com/media/1934616/icpdas_bmp_Logo_Logo.jpg
(PRNewsfoto/ICP DAS Co., Ltd.)
Source: ICP DAS Co., Ltd.
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
